ES2684094T3 - Forma cristalina I del ibrutinib - Google Patents
Forma cristalina I del ibrutinib Download PDFInfo
- Publication number
- ES2684094T3 ES2684094T3 ES14866302.4T ES14866302T ES2684094T3 ES 2684094 T3 ES2684094 T3 ES 2684094T3 ES 14866302 T ES14866302 T ES 14866302T ES 2684094 T3 ES2684094 T3 ES 2684094T3
- Authority
- ES
- Spain
- Prior art keywords
- ibrutinib
- crystalline form
- alkane
- mixture
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title claims abstract description 45
- 229960001507 ibrutinib Drugs 0.000 title claims abstract description 45
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title claims abstract description 45
- 239000013078 crystal Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 25
- 230000005855 radiation Effects 0.000 claims abstract description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 7
- 150000002576 ketones Chemical class 0.000 claims description 7
- 229910016523 CuKa Inorganic materials 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000025036 lymphosarcoma Diseases 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000002411 thermogravimetry Methods 0.000 description 7
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 6
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000037914 B-cell disorder Diseases 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 4-phenoxyphenyl Chemical group 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 229910005429 FeSSIF Inorganic materials 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310616065 | 2013-11-27 | ||
| CN201310616065.4A CN103694241A (zh) | 2013-11-27 | 2013-11-27 | Pci-32765的新晶型a及其制备方法 |
| CN201410542609.1A CN104327085B (zh) | 2013-11-27 | 2014-10-14 | Pci-32765的晶型a及其制备方法 |
| CN201410542609 | 2014-10-14 | ||
| PCT/US2014/067586 WO2015081180A1 (en) | 2013-11-27 | 2014-11-26 | Crystalline form i of ibrutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2684094T3 true ES2684094T3 (es) | 2018-10-01 |
Family
ID=50355928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14866302.4T Active ES2684094T3 (es) | 2013-11-27 | 2014-11-26 | Forma cristalina I del ibrutinib |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9751889B2 (enExample) |
| EP (1) | EP3073999B1 (enExample) |
| JP (1) | JP6483126B2 (enExample) |
| CN (2) | CN103694241A (enExample) |
| AU (1) | AU2014354728B2 (enExample) |
| CA (1) | CA2932059C (enExample) |
| DK (1) | DK3073999T3 (enExample) |
| ES (1) | ES2684094T3 (enExample) |
| HU (1) | HUE039718T2 (enExample) |
| IL (1) | IL245865B (enExample) |
| MX (1) | MX363265B (enExample) |
| PL (1) | PL3073999T3 (enExample) |
| PT (1) | PT3073999T (enExample) |
| WO (1) | WO2015081180A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3218491A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| US9884869B2 (en) | 2014-03-27 | 2018-02-06 | Perrigo Api Ltd. | Ibrutinib solid forms and production process therefor |
| CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
| MX2017001671A (es) | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. |
| CA2958139A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
| CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
| US10477780B2 (en) * | 2015-02-13 | 2019-11-19 | Hgci, Inc. | Multiple cell tray with media plugs |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| WO2016150349A1 (zh) * | 2015-03-20 | 2016-09-29 | 苏州晶云药物科技有限公司 | 一种pci-32765晶型a的制备方法 |
| CN106153797B (zh) * | 2015-04-20 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种依鲁替尼及依鲁替尼制剂有关物质分析方法 |
| CN106153798B (zh) * | 2015-04-22 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途 |
| WO2017029586A1 (en) * | 2015-08-19 | 2017-02-23 | Sun Pharmaceutical Industries Limited | Crystalline forms of ibrutinib |
| ITUB20155616A1 (it) * | 2015-11-16 | 2017-05-16 | Laboratorio Chimico Int S P A | Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina. |
| CN105294696A (zh) * | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| CN106905320A (zh) * | 2015-12-23 | 2017-06-30 | 杭州容立医药科技有限公司 | 一种适合药用的依鲁替尼及其制剂 |
| CN106995445B (zh) * | 2016-01-22 | 2021-08-03 | 山东新时代药业有限公司 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
| CN107286163A (zh) * | 2016-03-30 | 2017-10-24 | 上海星泰医药科技有限公司 | 一种依鲁替尼的新晶型及其制备方法 |
| CZ2016196A3 (cs) | 2016-04-06 | 2017-10-18 | Zentiva, K.S. | Pevné formy Ibrutinibu |
| CZ2016276A3 (cs) | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
| CN106117214A (zh) * | 2016-06-29 | 2016-11-16 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| CN106008529A (zh) * | 2016-08-08 | 2016-10-12 | 上海工程技术大学 | 一种依鲁替尼溶剂化物及其制备方法 |
| US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
| WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | Novel forms of ibrutinib |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
| US20220009929A1 (en) | 2018-05-02 | 2022-01-13 | Cipla Limited | Polymorphic forms of ibrutinib |
| EP3787751A1 (en) | 2018-05-03 | 2021-03-10 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| CN112313214A (zh) | 2018-06-19 | 2021-02-02 | 默克专利有限公司 | 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法 |
| CN111138436A (zh) * | 2018-11-04 | 2020-05-12 | 鲁南制药集团股份有限公司 | 伊布替尼晶型a单晶及其制备方法 |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| CN113214261A (zh) * | 2020-01-21 | 2021-08-06 | 尚科生物医药（上海）有限公司 | 一种依鲁替尼晶型a的纯化方法 |
| US11433072B1 (en) * | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| MA63498A1 (fr) | 2021-06-10 | 2024-07-31 | Hikma Pharmaceuticals Usa Inc. | Formes posologiques orales d'ibrutinib |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2645583A1 (en) | 2006-03-20 | 2007-09-27 | F. Hoffman-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| PT2201840E (pt) * | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| RU2013109393A (ru) | 2010-08-10 | 2014-09-20 | Сэлджин Авиаломикс Ресеарч, Инк. | Безилатная соль ингибитора втк |
| US9522917B2 (en) | 2012-04-11 | 2016-12-20 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CA3218491A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| CN103142601A (zh) * | 2013-03-13 | 2013-06-12 | 杭州雷索药业有限公司 | Pci-32765在制备抗血管生成类药物中的应用 |
-
2013
- 2013-11-27 CN CN201310616065.4A patent/CN103694241A/zh active Pending
-
2014
- 2014-10-14 CN CN201410542609.1A patent/CN104327085B/zh active Active
- 2014-11-26 HU HUE14866302A patent/HUE039718T2/hu unknown
- 2014-11-26 AU AU2014354728A patent/AU2014354728B2/en active Active
- 2014-11-26 PT PT14866302T patent/PT3073999T/pt unknown
- 2014-11-26 ES ES14866302.4T patent/ES2684094T3/es active Active
- 2014-11-26 MX MX2016006901A patent/MX363265B/es unknown
- 2014-11-26 PL PL14866302T patent/PL3073999T3/pl unknown
- 2014-11-26 EP EP14866302.4A patent/EP3073999B1/en active Active
- 2014-11-26 JP JP2016535162A patent/JP6483126B2/ja active Active
- 2014-11-26 CA CA2932059A patent/CA2932059C/en active Active
- 2014-11-26 US US15/100,247 patent/US9751889B2/en active Active
- 2014-11-26 DK DK14866302.4T patent/DK3073999T3/en active
- 2014-11-26 WO PCT/US2014/067586 patent/WO2015081180A1/en not_active Ceased
-
2016
- 2016-05-26 IL IL245865A patent/IL245865B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL245865A0 (en) | 2016-07-31 |
| CN103694241A (zh) | 2014-04-02 |
| JP6483126B2 (ja) | 2019-03-13 |
| AU2014354728A1 (en) | 2016-06-16 |
| US20170002009A1 (en) | 2017-01-05 |
| AU2014354728B2 (en) | 2019-02-28 |
| HUE039718T2 (hu) | 2019-02-28 |
| MX363265B (es) | 2019-03-19 |
| EP3073999B1 (en) | 2018-05-30 |
| PT3073999T (pt) | 2018-10-16 |
| CN104327085A (zh) | 2015-02-04 |
| CN104327085B (zh) | 2016-08-24 |
| CA2932059C (en) | 2019-07-02 |
| JP2016538314A (ja) | 2016-12-08 |
| DK3073999T3 (en) | 2018-09-03 |
| IL245865B (en) | 2019-05-30 |
| US9751889B2 (en) | 2017-09-05 |
| WO2015081180A1 (en) | 2015-06-04 |
| PL3073999T3 (pl) | 2018-10-31 |
| MX2016006901A (es) | 2016-10-28 |
| CA2932059A1 (en) | 2015-06-04 |
| EP3073999A4 (en) | 2017-03-22 |
| EP3073999A1 (en) | 2016-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2684094T3 (es) | Forma cristalina I del ibrutinib | |
| WO2022237815A1 (en) | Novel forms of Compound I and use thereof | |
| TWI586668B (zh) | 二螺吡咯啶衍生物之結晶 | |
| CN105732589A (zh) | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 | |
| WO2017016463A1 (zh) | Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| WO2017107985A1 (zh) | 喹唑啉衍生物的晶体及其制备方法 | |
| KR102874906B1 (ko) | Syk 억제제의 염 및 이의 결정형 | |
| CN105712996A (zh) | Ipi-145的新晶型及其制备方法 | |
| WO2020244348A1 (zh) | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 | |
| US20220213060A1 (en) | Crystal Form of Quinazolinone Compound and Preparation Method Therefor | |
| CN116437915B (zh) | 一种吡咯并杂环类衍生物的晶型及其制备方法 | |
| AU2023256032A1 (en) | Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative | |
| WO2022083733A1 (zh) | 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途 | |
| TWI680977B (zh) | ｃ-Ｍｅｔ抑制劑之多晶形式及共晶 | |
| EP4631937A1 (en) | Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof | |
| RU2710013C2 (ru) | Полиморфные формы икотиниба и их применения | |
| RU2818103C2 (ru) | Соль ингибитора syk и ее кристаллическая форма | |
| WO2023041061A1 (zh) | 一种稠合二环类衍生物的可药用盐、晶型及其制备方法 | |
| WO2023230968A1 (zh) | Shp2抑制剂、其晶型及其制备方法与用途 | |
| US20210340142A1 (en) | Salt form and crystal form of novel azatricyclic compound and use thereof | |
| WO2023202706A1 (zh) | 硒杂环类化合物的盐型和晶型及其应用 | |
| WO2022237808A1 (zh) | 吡咯并嘧啶类化合物的晶型及其制备方法 | |
| CN117209500A (zh) | Shp2抑制剂、其晶型及其制备方法与用途 | |
| CN121194973A (zh) | Jak2抑制剂的形式和组合物 |